PVigilant Health, Dubai (2026)

27/09/2026

🚨 98% of Suspected ADRs Never Reach Pharmacovigilance Databases!

In clinical practice, healthcare professionals observe adverse drug reactions daily. But how many of these vital safety signals actually make it to official databases?

A landmark Systematic Literature Review (PRISMA-compliant) evaluated 38,962 patients across 11 studies to quantify the true gap between clinical detection and formal ADR reporting.

The findings are a critical wake-up call for global patient safety:

📊 Key Insights from the Study:

📉 The Reporting Gap: Non-reporting estimates ranged between 71.7% and 100%, with a staggering median non-reporting rate of 98.05%.

⚠️ Severity Doesn't Drive Action: Formal reporting remained consistently low—regardless of whether the adverse event was mild, severe, or life-threatening.

🛡️ Patient Safety Impact: Under-reporting creates massive blind spots in post-marketing surveillance, potentially delaying life-saving safety warnings.

💡 Why This Matters:

Under-reporting isn't just an administrative delay—it’s a direct patient safety risk. Closing this gap requires moving from passive reporting to proactive, clinician-led pharmacovigilance workflows.

Knowledge = Life 🌱

🔗 Full article reference & link in the 1st comment ⬇️

💬 To our Clinical & PV Community: What are the biggest operational barriers preventing healthcare professionals from submitting formal ADR reports in your institution? Let’s discuss below! 👇

🎯 Follow PVigilant Health for evidence-based drug safety insights, clinical PV strategies, and regulatory updates.

25/09/2026

Today, as the global healthcare community celebrates World Pharmacists Day, we pause to honor the critical, evolving role of pharmacists worldwide.

The days when a pharmacist's sole duty was dispensing medications are far behind us. Today, pharmacists stand at the forefront of clinical decision-making, polypharmacy management, and proactive Pharmacovigilance (PV).

🔍 Why Pharmacists are the Backbone of Medication Safety:

▪️The First Line of Signal Detection: Whether in a clinical setting, community pharmacy, or regulatory authority, pharmacists are often the first to identify subtle adverse drug reactions (ADRs) and potential drug-drug interactions.

▪️Bridge Between Evidence & Patient Care: Pharmacists translate complex pharmacological data and safety alerts into actionable, patient-centered care plans.

▪️Empowering Safe Rational Use: By conducting thorough medication reviews and advocating for deprescribing unnecessary treatments, pharmacists prevent avoidable hospitalizations every single day.

At PVigilant Health, we believe that medication safety is not an afterthought—it is an operational imperative. And at the heart of this imperative is the vigilant, knowledgeable pharmacist.

To every pharmacist, clinical specialist, PV officer, and researcher safeguarding patient health around the globe: Thank you for your unwavering vigilance.

Knowledge = Life 🌱

💬 To our Global PV & Pharmacy Community: What inspired you to choose the path of pharmacy and medication safety? Share your journey with us in the comments! 👇

🎯 Follow PVigilant Health for evidence-based drug safety insights, clinical PV strategies, and regulatory updates.

22/09/2026

🩸 Redefining Iron Deficiency: Why a Normal Ferritin May No Longer Mean 'Safe'

For decades, clinicians and pharmacovigilance teams have relied on a universal cutoff—a serum ferritin below 15 ng/ml to confirm iron deficiency.

However, the American Society of Hematology (ASH) 2026 Guidelines have officially shifted this paradigm. Waiting for ferritin to drop below 15 ng/mL leaves millions of symptomatic patients undiagnosed and unprotected.

📊 The New 2026 ASH Diagnostic Cutoffs:

🔹 Children (9 mos – 4 yrs): =< 20 ng/mL

🔹 Adults (including pregnant & menstruating individuals): =< 30 ng/mL

🔹 High-Risk / Symptomatic Patients (e.g., heavy uterine bleeding): Up to =< 50 ng/mL

🔹 Anemia of Inflammation (Cancer, IBD, Chronic Infection): Evaluate Ferritin + TSAT simultaneously TSAT< 20% or Ferritin < 100 ng/mL

(Note: Fasting for 5–9 hours, including withholding iron supplements, is recommended before TSAT testing).

🛡️ Why This Matters for Pharmacovigilance & Patient Safety:

▪️Drug-Induced Iron Malabsorption: Common drug classes (e.g., Proton Pump Inhibitors, Chronic NSAID use, Calcium supplements) frequently impair iron absorption or cause subtle GI micro-bleeds. Recognizing higher diagnostic cutoffs enables early detection of drug-induced iron depletion before severe anemia develops.

▪️Preventing High-Risk IV Iron Escalations: Late diagnosis often forces emergency intravenous iron administration, elevating the risk of acute hypersensitivity reactions. Early diagnosis allows for safer, managed oral or low-risk therapeutic pathways.

▪️Lab Reference Range vs. Clinical Limits: Standard lab "normal ranges" do not equal clinical safety. True vigilance requires evaluating patient symptoms in clinical context rather than relying solely on automated lab flags.

Safety isn't just about tracking adverse events—it's about ensuring timely, accurate clinical decisions that prevent patient deterioration. 🌿

Knowledge = life 🌱

💬 To our Clinical & PV Community: How is your institution updating its clinical decision limits and lab reporting thresholds following the new 2026 ASH guidelines? Let's discuss below! 👇

20/09/2026

In Pharmacovigilance, raw data alone isn't enough; it is the structured clinical knowledge derived from that data that transforms patient safety. 📊💡

When an adverse reaction report enters a database, it's a single observation. But when aggregated, evaluated through causality assessments, and matched against real-world evidence (RWE), it becomes actionable intelligence.

As Francis Bacon famously stated:

"Knowledge itself is power."

🛡️ How Knowledge Empowers Drug Safety & PV:

▪️Data to Intelligence:
Transforming vast streams of ICSRs (Individual Case Safety Reports) into meaningful safety signals requires deep analytical rigor and systematic data mining.

▪️Proactive Risk Mitigation:
Early knowledge allows regulatory authorities and MAH safety teams to update product labelling, issue Direct Healthcare Professional Communications (DHPCs), and implement Risk Minimisation Measures (RMMs) before widespread harm occurs.

▪️Empowering Clinical Decision-Making:
Providing healthcare professionals with clear, evidence-based safety data equips them to make safer prescribing choices tailored to patient risk profiles.

In our field, knowledge isn't just theoretical; it is the most critical tool for saving lives and ensuring long-term drug safety. 🌿

💬 To our PV & Regulatory Community: How is your team leveraging modern data analytics to turn raw PV reports into actionable safety knowledge? Share your approach below!

🎯 Follow PVigilant Health for strategic drug safety insights, regulatory analyses, and timeless clinical wisdom.

Knowledge = life 🌱

16/09/2026

Managing Non-Communicable Diseases (NCDs), such as cardiovascular conditions, diabetes, and chronic respiratory disorders, rarely involves a single medication. Most patients rely on complex, lifelong, multi-drug regimens.

While these therapies save lives, polypharmacy dramatically escalates the risk of Adverse Drug Reactions (ADRs), unrecognised drug-drug interactions, and organ toxicities over time.

On this World Patient Safety Day, we align with the World Health Organisation (WHO) to emphasise that safe care for NCDs requires proactive pharmacovigilance at every step:

🔹 Drug Interaction Screening: Identifying potential metabolic bottlenecks (like CYP450 enzyme inhibition or induction) before prescribing.

🔹 Continuous Risk Assessment: Regularly re-evaluating long-term therapy to adjust dosages or deprescribe unnecessary drugs.

🔹 Proactive Signal Detection: Monitoring real-world data to capture subtle, cumulative adverse reactions in chronic patients early.

Effective NCD management goes beyond prescribing treatment—it demands protecting the patient throughout their entire therapeutic journey. 🌿

💬 To our Clinical & PV Professionals: How does your institution actively screen for polypharmacy risks in chronic disease clinics? Share your insights below! 👇

Knowledge = life 🌱

14/09/2026

We are proud to announce that Dr. Ahmed Hegazy, Director of PVigilant Health and Co-Chair of the ISoP MENA Chapter, will be a featured speaker at the upcoming International Society of Pharmacovigilance (ISoP) Patient Safety Day 2026!

🎤 Session Title:

“Pharmacovigilance in Non-Communicable Diseases: From Drug Safety to Safe Care”

In this session, Dr. Hegazy will explore how modern pharmacovigilance must evolve beyond traditional adverse event reporting to actively shape integrated, safer care pathways for patients battling chronic conditions.

📅 Event Details:

▪️Date: September 17, 2026
▪️Time: 16:00 UTC | 18:00 Egypt | 20:00 Dubai
▪️Format: Virtual Session (Free Access)

🔗 Registration Link: Full details & registration link in the 1st comment ⬇️

Knowledge = life 🌱

13/09/2026

From chemotherapy-induced peripheral neuropathy (CIPN) to life-threatening Posterior Reversible Encephalopathy Syndrome (PRES), Drug-Induced Neurotoxicity (DINT) presents a major clinical challenge that directly impacts patient quality of life and treatment continuity. 🧠⚡

Early detection and aggressive dose adjustments are critical before transient symptoms become permanent neurological deficits.

Our latest reference visual outlines 6 high-risk therapeutic classes associated with central and peripheral neurotoxicity:

🔬 Oncology Regimens: Managing platinum-induced dysesthesia, Vinca alkaloid microtubule damage, and CAR-T cell ICANS.

💊 Anti-Infectives & Immunosuppressants: Preventing Isoniazid paresthesia with B6 supplementation and identifying Tacrolimus-induced PRES.

📊 CNS & Anti-Seizure Agents: Tracking TDM for Lithium/Phenytoin and managing ataxia risks.

💬 To our PV & Clinical Community: What neurotoxicity screening protocol or dose-modification workflow has been most effective in your oncology or ICU units? Share your experience below!

Knowledge = life 🌱

10/09/2026

Did you know that 90% of the picture is often missing in daily clinical practice? 🕵️‍♂️📈

One of the greatest challenges in Pharmacovigilance is under-reporting. Spontaneous reporting remains the cornerstone of drug safety surveillance post-marketing, yet global estimates suggest that only a fraction of severe Adverse Drug Reactions (ADRs) are ever reported to regulatory authorities or pharmaceutical companies.

🌟 Why this matter is critical:

When ADRs aren't reported, we miss the signals. Signal detection depends on robust data. Under-reporting delays the identification of rare or new safety signals, potentially hindering the implementation of vital risk-minimization measures like label updates, Black Box warnings, or even drug withdrawals.

🚫 Common Barriers to Reporting (The Why):

1.Clinical Inertia:
Assuming the reaction is already known or that reporting won't make a difference.

2.Ignorance:
Not knowing how or where to report, or misidentifying causality.

3.Time Constraints:
The busy pace of routine clinical practice.

4.Fear:
Concerns about potential medical-legal implications.

🛡️ The Clinician's Call to Action:

As PV & Clinical professionals, we must move from passive monitoring to proactive vigilance. Every reporter matters.

💬 To our Clinical & PV Community: What is the biggest barrier you’ve observed (or experienced) preventing routine ADR reporting in your healthcare setting? Let's discuss strategies to overcome it below! 👇

🎯 Follow PVigilant Health for strategic drug safety insights, Real-World Evidence (RWE) analyses, and practical clinical wisdom.

Knowledge = life 🌱

08/09/2026

🚨 BE VIGILANT | Clopidogrel is one of the most widely prescribed antiplatelet therapies globally to prevent cardiovascular events and stent thrombosis. However, its effectiveness relies entirely on a critical metabolic activation step. 🫀⚠️

As a prodrug, Clopidogrel requires biotransformation by hepatic cytochrome P450 enzymes—primarily CYP2C19—to form its active metabolite.

Without sharp clinical vigilance and pharmacogenomic consideration, standard therapy can fail quietly with severe thrombotic consequences.

Key safety signals and clinical safeguards for PV professionals and clinicians:

⚠️ The Genetic Bottleneck: Up to 14% of patients carry loss-of-function CYP2C19 alleles (*2 or *3). These "poor metabolizers" form significantly less active drug, resulting in reduced antiplatelet action and elevated cardiovascular risk.

🚫 Drug-Drug Interaction Pitfalls: Concomitant use of strong or moderate CYP2C19 inhibitors—such as Omeprazole or Esomeprazole—sharply reduces active metabolite levels and should be avoided.

🛡️ The Safeguard Strategy: Consider CYP2C19 genotype testing in high-risk patients (e.g., post-PCI). In verified poor metabolizers, guidelines recommend switching to alternative antiplatelet agents like Prasugrel or Ticagrelor.

Effective antiplatelet therapy requires knowing whether your patient can actually activate the drug. 🌿

💬 To our cardiology & clinical pharmacy team: Do you routinely screen for CYP2C19 interactions or switch PPIs to Pantoprazole when prescribing Clopidogrel? Share your practical experience below!

Knowledge = life 🌱

06/09/2026

Is your drug safety architecture built to keep pace with modern regulatory expectations and advanced therapeutics? 🧬⚡

Pharmacovigilance (PV) is evolving rapidly beyond routine adverse event reporting. Today, integrating PV data and practices directly into Quality Management (QM) systems and regulatory decision-making is no longer just best practice—it is an operational imperative throughout the entire medicinal product lifecycle.

A recent Systematic Review (2020–2025) analyzing key literature across PubMed, Scopus, and Web of Science synthesizes the critical advancements and persistent gaps shaping the future of global drug safety.

Full study link in the 1st comment ⬇️

💬 To our PV, QA, and Regulatory Leaders: How is your organization currently aligning PV signal detection workflows with your broader Quality Management Systems (QMS)? Let’s exchange insights below! 👇

Knowledge = life 🌱

PVigilant Health

27/09/2026

25/09/2026

22/09/2026

20/09/2026

16/09/2026

14/09/2026

13/09/2026

10/09/2026

08/09/2026

06/09/2026

Address

Website

Alerts

Contact The Business

Shortcuts

Share

Category

Listing takedown request